University of California, San Diego, School of Medicine, San Diego, California, USA.
Ann Intern Med. 2010 Oct 19;153(8):532-5. doi: 10.7326/0003-4819-153-8-201010190-00010.
No regulations govern placebo composition. The composition of placebos can influence trial outcomes and merits reporting.
To assess how often investigators specify the composition of placebos in randomized, placebo-controlled trials.
4 English-language general and internal medicine journals with high impact factors.
3 reviewers screened titles and abstracts of the journals to identify randomized, placebo-controlled trials published from January 2008 to December 2009.
Reviewers independently abstracted data from the introduction and methods sections of identified articles, recording treatment type (pill, injection, or other) and whether placebo composition was stated. Discrepancies were resolved by consensus.
Most studies did not disclose the composition of the study placebo. Disclosure was less common for pills than for injections and other treatments (8.2% vs. 26.7%; P = 0.002).
Journals with high impact factors may not be representative.
Placebos were seldom described in randomized, controlled trials of pills or capsules. Because the nature of the placebo can influence trial outcomes, placebo formulation should be disclosed in reports of placebo-controlled trials.
目前尚无规范来约束安慰剂的组成。安慰剂的组成可能会影响试验结果,值得报告。
评估随机、安慰剂对照试验中研究者报告安慰剂组成的频率。
4 种影响因子较高的英文普通医学和内科期刊。
3 位评价者筛选期刊的标题和摘要,以确定 2008 年 1 月至 2009 年 12 月发表的随机、安慰剂对照试验。
评价者独立地从确定文章的引言和方法部分提取数据,记录治疗类型(药丸、注射剂或其他)和安慰剂组成是否被描述。通过共识解决分歧。
大多数研究未披露研究安慰剂的组成。与注射剂和其他治疗方法相比,药丸的披露较少(8.2%对 26.7%;P = 0.002)。
高影响因子的期刊可能不具有代表性。
随机对照试验中对药丸或胶囊很少描述安慰剂。由于安慰剂的性质可能会影响试验结果,因此应在安慰剂对照试验报告中披露安慰剂的配方。